Have you ever wanted to write an official ATS clinical practice guideline or technical statement or workshop report but didn’t know where to start?
Then THIS podcast is for you! 🤩
Just out from @ats-clinicalprobs.bsky.social
@ats-assemblies.bsky.social
youtu.be/7DIJRdQDu2o?...
Screen shot of study title and authors
The most impactful clinical ILD study in ages! 🌟
True multidisciplinary collaboration driving progress 🫁
@rogerjlewis.bsky.social @ipfdoc.bsky.social
A Statistical Model for Lung Function Trajectory and Mortality in Patients with Fibrotic ILD
academic.oup.com/ajrccm/advan...
#OpenAccess
I thought he was playing golf?
Multidisciplinary Videoconferencing for Physician Education and Remote Management of Interstitial Lung Disease
@atscommunity.bsky.social #medsky
🔗 tinyurl.com/2cjt69hv
I wonder how much of my life has been wasted resetting passwords! 😫😫
@delanghelab.bsky.social @tatalab-duke.bsky.social @ipfdoc.bsky.social @kottond.bsky.social @msbr89.bsky.social @varelaslab.bsky.social @lisyvila.bsky.social @carolavoss.bsky.social Please reshare! Thank you :)
Time to stop publishing conference abstracts as AI will not distinguish quality between published abstract and published original research? @atsblueeditor.bsky.social @bmj.com
Indeed as if by magic this person/group/bot posted a heartwarming story about Ivy decontaminating mold spores. Trouble is beyond a 1993 abstract this was NEVER published in JACI, therefore heartwarming but probably wrong. DO NOT trust sources that can not be independently verified. Also…
@kaminskimed.bsky.social @kerrijohannson.bsky.social @charlottesummers.bsky.social
www.rollingstone.com/culture/cult...
Is this the unavoidable endpoint when knowledge, ego and career converge? This is a chilling article which clearly needs the academic community to find a solution, but we need to rethink how we reward academic endeavour. #NoMorePublishOrPerish
Wow! As somebody who shares your rabies paranoia that is a pretty low bar for ruling out infectious causes of sudden death and harvesting lungs. 😳
Thank you so much for your hospitality @kaminskiMed. It was wonderful to interact with so many smart, talented and enthusiastic investigators and experience what an amazing environment you get to live and work in.
Oh no - now I gotta go 👔shopping! 😂 Maybe I’ll bring a tie?! 🤔😂
Would be lovely to get your perspective.
You are too kind!
Oh yes! 😂😂
One of the greatest shows on TV ever. I was particularly amused by the interpretation of the carrot and stick approach. 😂
The most exciting papers of the year! Could these observers provide insights into the potential of immunotherapy in other conditions? 🤔
This is a really great thread 🧵 about an important study using mixed methodology to understand a subject that rarely gets the attention it deserves. Kudos to the team @ucalgary.bsky.social guided by the brilliant @kerrijohannson.bsky.social
Would be fascinating to do an SR+MA on AF as co-meds in trials vs IMP in trials? 🤔
For sure there is no dose response really for Pirfenidone some dose response for nintedanib but really good point!
No, in London.
However, another study highlighting the disappearing treatment effect! Check the placebo vs Pirfenidone groups! 😳😳 we really need better drugs to #CureIPF
TETON-2 data looking good! 96ml of FVC ‘saved’ by inhaled treprostinil at 12 months. Devil will be in detail but all very promising.
youtu.be/zTs3PDEkB2w
Interesting story.
1) Brexit actually increased migration.
2) Students r source of UKs immigration‘problem’, likely due to our outstanding universities
3) Cumulative asylum seeker retention builds up
4) A ‘hostile environment’ might work but at what cost & for what impact? 😬
Pogacar vs Vingegaard?
Alcaraz vs Sinner?
Tottenham vs Arsenal?
Giants vs Dodgers?
Nemesis vs motivation?
I think this is a great idea, might be tricky to operationalise.
The current system is breaking if not already broken.
Incentivises research fraud.
Will prevent people seeing the wood because of all the dodgy trees.
#LessIsMore
This makes me sad (not altogether sure why), but I would like thank #DanielLevy for his hard work over last 25 yrs. The Stadium, European Glory Nights, Great teams, superstar players! 😍 There were some lows I’m sure but I don’t remember those. #COYS
Phenomenal result! FIRST positive 52 week study of inhaled therapy in #IPF. Benefits were independent of background therapy! 🤩
Along with Nerandomilast this shows importance of cAMP/PDE4 pathways in fibrosis & opens door 4 other therapies targeting these pathways!
#FutureLooksBright #CureIPF
Text of primary and secondary endpoints
TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁
Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD
@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
www.theglobeandmail.com/investing/ma...